Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 4, 2020– Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization…
FDA Approves Merck’s Keytruda (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
KENILWORTH, N.J.–(BUSINESS WIRE) November 13, 2020 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has…
ImmunityBio, NantKwest Announce Positive Interim Phase 1 Safety Data of hAd5 COVID-19 Vaccine Dose Study
CULVER CITY & EL SEGUNDO, Calif., November 10, 2020 — ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have…
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) — Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the…
Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn’s Disease in 52-Week Phase 2 Trial
INDIANAPOLIS, Oct. 12, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) announced today new efficacy and safety data from the Phase 2 SERENITY study evaluating mirikizumab in patients with moderately to severely active…
Lilly Announces Arrangement for Supply of Potential COVID-19 Antibody Therapy for Low- and Middle-Income Countries
INDIANAPOLIS, Oct. 8, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an agreement to…
FDA Approves Additional Doses of Trulicity (dulaglutide) for the Treatment of Type 2 Diabetes
INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) today approved two additional doses of Eli Lilly and Company’s (NYSE: LLY) Trulicity® (dulaglutide). The approval expands the label of once-weekly Trulicity to…
Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis
WILMINGTON, Del.–(BUSINESS WIRE)–Jan. 28, 2020– Incyte (Nasdaq:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD2 study evaluating the safety and efficacy of ruxolitinib cream in adolescent and…
Rise in serious harm to children caused by powerful painkillers, says study
The proportion of high-strength painkiller poisonings among children which result in emergency hospital admissions has increased, according to research published in the peer-reviewed journal Clinical Toxicology. A study involving more…
Regional trends in overdose deaths reveal multiple opioid epidemics, according to new study
The United States is suffering from several different simultaneous opioid epidemics, rather than just a single crisis, according to an academic study of deaths caused by drug overdoses. David Peters,…